Working… Menu

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01844778
Recruitment Status : Completed
First Posted : May 1, 2013
Results First Posted : May 24, 2016
Last Update Posted : July 27, 2016
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The purpose of this interventional Phase IV study was to explore the ease of use of TIP and prevalence of microbial contamination of the T-326 Inhaler compared with TIS and colistimethate administered via nebuliser for the treatment of Cystic Fibrosis (CF) patients chronically infected with P. aeruginosa.

It was anticipated that the data from this study would provide clinicians with further guidance on the relative differences between the speed and ease of use of these treatments as well as useful information on the prevalence of microbial contamination of the inhalation devices in "real world" use.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: Tobramycin Inhalation Powder Drug: Tobramycin inhalation solution Drug: Colistimethate Phase 4

Detailed Description:
Patients who were on colistimethate (COLI), Tobramycin Inhalation Powder (TIP) or Tobramycin Inhalation Solution (TIS) were recruited for the study. They went through one treatment cycle on their usual inhaled antibiotic treatment, and were all transferred to TIP for the second treatment cycle. The primary endpoint was the total administration time of TIP vs TIS vs colistimethate, defined as the total time taken to prepare the delivery device and drug, administer the drug, and clean and disinfect the delivery device.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Crossover, Interventional Phase IV Study to Compare the Ease of Use of TIP With Nebulized TIS and Nebulized COLI for the Treatment of Pulmonary Pseudomonas Aeruginosa (P.a) in Patients With Cystic Fibrosis
Study Start Date : August 2013
Actual Primary Completion Date : October 2015
Actual Study Completion Date : October 2015

Arm Intervention/treatment
Active Comparator: TIS/TIP
During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
Drug: Tobramycin Inhalation Powder
Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
Other Name: TIP

Drug: Tobramycin inhalation solution
Tobramycin inhalation solution was administered via nebuliser
Other Name: TIS

Active Comparator: COLI/TIP
During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
Drug: Tobramycin Inhalation Powder
Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
Other Name: TIP

Drug: Colistimethate
Colistimethate was administered via nebuliser.
Other Name: COLI

Active Comparator: TIP/TIP
During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
Drug: Tobramycin Inhalation Powder
Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
Other Name: TIP

Primary Outcome Measures :
  1. Mean Total Administration Time [ Time Frame: days 22 through 28 (cycle 1), days 78 through 84 (cycle 2) ]
    The mean total time for administration of TIP via T-326 inhaler versus the total time for administration of COLI or TIS was assessed from information entered by participants into an ediary during the last 7 days prior to the last dose of a cycle. The total time included the setup, preparation, administration and cleaning/disinfection time.

Secondary Outcome Measures :
  1. Change in P. Aeruginosa Sputum Density [ Time Frame: days 1, 28 (cycle 1); 57, 84, 112 (cycle 2) ]
    Sputum samples were sent to a central laboratory at the start and end of 2 treatment periods. The absolute change in the number of colony forming units (CFU) of Pseudomonas aeruginosa in sputum = the value of end of on/off treatment period of the cycle minus the pre-dose value at the start of that cycle. A negative change from baseline indicates improvement.

  2. Number of Participants With Any Contaminated Delivery Device [ Time Frame: days (d) 1, 28, 57, 84 ]
    Devices used to administer the drugs (the T-326 inhaler and nebulisers) were swabbed for contamination testing at the start and end of each treatment cycle (or discontinuation visit if the participant withdrew). No assessments were required from the T-326 inhaler when participants started the treatment period (days 1 and 57). Microbial contamination was measured according to device type and the frequency of organism growth (light/ moderate/ heavy). All nebulisers (neb) used by the participants were analyzed, including those for inhaling other medications, like mucolytics.

  3. Minimum Inhibitory Concentration (MIC) - MIC50 and MIC90 Tobramycin Values [ Time Frame: days 1, 28, 57, 84, 112 ]
    MIC50/90 is the lowest concentration required to inhibit 50%/90% of the isolates tested. The MIC50/90 of a range of antibiotics for P.aeruginosa was determined at the start and end of each treatment cycle, and at the end of the off-treatment period of the second cycle.

  4. Number of Participants With Post-inhalation Bronchospasm [ Time Frame: days 1, 28, 57, 84 ]
    Bronchospasm was defined as the relative decrease of 20% or more in forced expiratory volume in 1 second (FEV1) percent predicted from pre-dose to 15 to 45 minutes post-dose.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Provide written informed consent, HIPAA authorization, and assent (as appropriate for minors) prior to the performance of any study-related procedure
  • Confirmed diagnosis of Cystic Fibrosis (CF)
  • Male and female patients 6 years of age or older at screening
  • Forced Expiratory Volume in 1 second (FEV1) at screening (Visit 1) must be at least 25% and less than or equal to 90% of normal predicted values for age, sex, and height based on the NHANES III values (Hankinson, 1999) for patients 18 years of age or greater, and based on values from Wang (Wang 1993) for patients less than 18 years of age.
  • Documented use of any of the nebulized antibiotics based on local practice:
  • Tobramycin Inhalation Solution, colistimethate, or Tobramycin Inhalation Powder for at least 1 cycle within the last 6 months or
  • Colistimethate continuous use for at least 8 weeks within the last 6 months This cycle of treatment (or continuous colistimethate treatment period) is in addition to the treatment cycle during which the subject is being screened.
  • P. aeruginosa must be present in a sputum or deep cough throat swab culture or bronchoalveolar lavage (BAL) (only for BAL a threshold level of 10^3 CFU/mL is required) within 6 months prior to screening, and in the sputum or deep cough throat swab culture at screening or rescreening (Visit 1);

Key Exclusion Criteria:

  • History of sputum culture or deep cough throat swab (or BAL) culture yielding Burkholderia cenocepacia complex within 2 years prior to prescreening or sputum culture yielding B. cenocepacia complex at screening (Visit 1)
  • History of hearing loss or chronic tinnitus deemed clinically significant by the investigator
  • Serum creatinine 176.8 μmol/L (2 mg/dL) or greater, blood urea nitrogen (BUN) 14.28 mmol/L (40 mg/dL) or greater, or an abnormal urinalysis defined as 2+ or greater proteinuria at screening
  • Known local or systemic hypersensitivity to aminoglycosides
  • Regularly receiving more than 1 class of inhaled antipseudomonal antibiotic
  • Use of any investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening
  • Signs and symptoms of acute pulmonary disease, e.g., pneumonia, pneumothorax
  • Body mass index less than 12 kg/m2
  • History of malignancy of any organ system, treated or untreated
  • Clinically significant laboratory abnormalities (not associated with the study indication) at screening (Visit 1)
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during study treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01844778

Layout table for location information
Novartis Investigative Site
Berlin, Germany, 13353
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
München, Germany, 81241
Novartis Investigative Site
Tübingen, Germany, 72076
Novartis Investigative Site
Galway, Ireland
Novartis Investigative Site
Sevilla, Andalucia, Spain, 41013
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Palma De Mallorca, Islas Baleares, Spain, 07120
Novartis Investigative Site
Madrid, Spain, 28046
Novartis Investigative Site
Basel, Switzerland, 4031
Novartis Investigative Site
St. Gallen, Switzerland, 9007
Novartis Investigative Site
Zürich, Switzerland, 8032
United Kingdom
Novartis Investigative Site
Southampton, Hampshire, United Kingdom, SO16 6YD
Novartis Investigative Site
Penarth, Vale of Glamorgan, United Kingdom, CF64 2XX
Novartis Investigative Site
Birmingham, West Midlands, United Kingdom, b9 5ss
Novartis Investigative Site
Bristol, United Kingdom, BS1 3NU
Novartis Investigative Site
East Yorkshire, United Kingdom, HU16 5JQ
Novartis Investigative Site
Exeter, United Kingdom, EX2 5DW
Novartis Investigative Site
Liverpool, United Kingdom, L14 3PE
Novartis Investigative Site
Newcastle upon Tyne, United Kingdom, NE1 4LP
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01844778    
Other Study ID Numbers: CTBM100C2403
2012-001565-33 ( EudraCT Number )
First Posted: May 1, 2013    Key Record Dates
Results First Posted: May 24, 2016
Last Update Posted: July 27, 2016
Last Verified: July 2016
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI,
Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI, colistimethate
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Anti-Bacterial Agents
Anti-Infective Agents